• Email:
  • Password:
  • Remember Me
 
Lecture Hall General Diabetes | Review

Diabetes Mellitus


Jeffrey M.  Robbins
Jeffrey M. Robbins, DPM
Director, Podiatry Services
VA Central Office
Louis Stokes Cleveland VAMC
Cleveland, OH
System Requirements Method of Participation Disclosure Information
Lecture Transcription


1



The podiatric practitioner must have a strong working knowledge of not only the pedal complications of Diabetes Mellitus but also other systemic morbidity associated with this disease. It is no secret that Americans are getting more and more obese and with this increase obesity the concomitant rise in the prevalence of diabetes, especially type 2, is no coincidence. The purpose of this talk is to present an overall perspective of this disease from diagnosis through complications and management principals. If there is one essential take home message it would be that medicine today is not an individual pursuit, it is interdisciplinary and requires close communication and cooperation of patients, their families and the many health care providers that seek to control this disease and limit its complications.



2



Each year the American Diabetes Association publishes its Clinical Practice Recommendations which we will use as a reference. The most recent document is listed here and was released in January of 2004. This document is a compilation of hundreds of individual references that represent the most recent evidence and expert opinion. As new ADA Clinical Practice Recommendations are released I strongly encourage that you read over the changes made to the previous document.



3



At the outset it is essential today that health care providers understand the strength of the evidence upon which they are making management decisions. For this reason, the ADA has established a grading system to define those relative strengths.



A Level evidence indicates clear evidence from well-controlled, generalizable, randomized controlled trials that are adequately powered



B Level Evidence indicates Supportive evidence from well conducted cohort studies



C Level Evidence indicates Supportive evidence from poorly controlled or uncontrolled studies and



E Level Evidence indicates Expert consensus or clinical experience



It should be noted that the strength of this evidence helps us to define where our knowledge is lacking and should help direct research efforts in the future.



4



Lets begin with a general overview of diabetes as a systemic disease. As defined by the ADA“, Diabetes is a group of metabolic diseases involving carbohydrates, lipids and proteins. It is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heartand blood vessels.



5



The persistent hyperglycemiais caused by either an absolute deficiency (where the pancreas does not produce any insulin) or ineffective insulin (where there is either an underproduction or "insulin resistance.”)



6



The podiatric physician must be cognizant of the major complications of diabetes. The two most serious acute complications are ketoacidosis and hyperosmolar hyperglycemia. The mortality rates for ketoacidosis is around 5% and for hyperosmolar hyperglycemia around 15%. The most common precipitating factor for DKA or HHS is infection, others include stroke, alcohol abuse, pancreatitis, myocardial infarction, trauma and drugs. For both DKA and HHS the classic symptoms include polyurua, polydipsia, polyphagia, weight loss, vomiting, abdominal pain (in DKA) dehydration, weakness, mental status changes and finally coma. Hypoglycemia is a common complication in patients with diabetes that may present in your office. It is from a relative low blood sugar either from too much insulin or failure to eat properly. It is not uncommon for patients to lose consciousness in the office setting when hypoglycemic It is essential for the clinician to quickly determine if the loss of consciousness is due to hyperglycemia which is quickly reverses with oral glucose or the more serious diabetic ketoacidosis or hyperosmolar hyperglycemia. Infection is common in patients with diabetes and may be due to a decrease in the ability of white blood cells to fight infection. It is believed that prolonged periods of hyperglycemia may cause a decrease chemotaxis to the site, a decreased ability to phagocytize which results in decreased intracellular killing of bacteria



7



It is well know that cardiovascular diseases such as myocardial infarction, hypertension and stroke are more common in patients with diabetes. In fact the risk of Heart disease and Stroke is is 2-4 x greater in patients with diabetes and 73 % of all patients with diabetes have blood pressures 130/80 or above

Diabetes is the leading cause of blindness accounting for 12,000-24,000 new cases yearly and accounts for 43% of all Kidney disease. We are all well aware that 60% of non-traumatic amputations are seen in patients with diabetes which is estimated at 87,000 amputations from 1999-2001. The reason for this high amputation rate is due to the Negatively Synergistic Diabetes Foot Complications which include Ischemia, Neuropathy, and infection. Keep in mind that 85% of all non traumatic amputations were preceded by a foot ulceration



8



The standards for making the diagnosis of diabetes involves the evaluation of plasma glucose. Physiologically Insulin helps to metabolize glucose and transport it in a usable form of energy to the cells of the body. Without insulin, glucose can't be stored -- which results in a rise in the level of glucose in the blood. A blood glucose level of 126 milligrams per deciliter (mg/dL) or more after an overnight fast is considered abnormal. The diagnosis of diabetes is make when a fasting blood glucose level of 125mg/dl is confirmed on a subsequent day by either another fasting glucose, classic symptoms of polyuria, polydypsia and polyphagia and a glucometer reading of 200mg.dl or higher or a 2 hour fasting blood glucose of 200 mg/dl or greater in a 75gm oral glucose tolerance test



9



The two most common types of diabetes are type 1 and type 2

Type 1 diabetes occurs because the insulin-producing cells or beta cells of the pancreas are damaged and as a result they produce little or no insulin. People with type 1 diabetes must use insulin injections to control their blood glucose.

The damage to the insulin-producing cells in type 1 diabetes occurs over a period of years. However, the symptoms of type 1 diabetes may occur over a period of days to weeks. Type 1 diabetes most commonly starts in people under the age of 20, but may occur at any age. Unlike type 1 diabetes, people with type 2 diabetes produce insulin. The insulin they produce however is either in small quantities or doesn't work properly in the body. As a result glucose can't get into the body's cells. Type 2 diabetes is the most common form, affecting almost 17 million Americans. While over 91% of these cases can be prevented, it remains for adults a major cause of related complications. Type 2 diabetes usually starts in people over age 40 who are overweight; but can also occur in people who are not overweight. Sometimes referred to as "adult-onset diabetes,” type 2 diabetes has started to appear in children because of the rise in obesity in young people.



Gestational Diabetes. Gestational diabetes is triggered by pregnancy. Hormone changes during pregnancy can affect insulin's ability to work properly, resulting in high blood glucose levels. Pregnant women who have an increased risk of developing gestational diabetes are those who are over 25 years old, are above their normal body weight before pregnancy, have a family history of diabetes or are Hispanic, black, Native American, or Asian. Usually, blood glucose levels return to normal after childbirth. However, women who have had gestational diabetes have an increased risk of developing type 2 diabetes later in life. Other Specific Types of diabetes include genetic defects of beta cells or of insulin itself, disease of the pancreas, endocrinopathies, drugs or chemically induced diabetes and infections.



10



The 2002 Clinical Practice Recommendations has added a new classification of diabetes termed “pre diabetes” This new class is for patients with impaired fasting glucose defined by a fasting plasma glucose of 100-125mg/dl or impaired glucose tolerance define by a 2 hour post load glucose of 140-199mg/dl This class is not treated as diabetes but represent a significant risk factor of frank diabetes and cardiovascular disease



11

Symptoms of diabetes often occur suddenly and can be severe. They may include increased thirst, increased hunger, dry mouth, blurred vision, numbness or tingling of the hands and feet, loss of consciousness increased urination, frequent urination, unexplained weight loss, and fatigue. These symptoms usually develop quickly, over a few days to weeks. Occasionally symptoms are first noticed after an illness, such as the flu. The person may think the diabetes symptoms are related to the illness and not seek medical care early.



12



The blood sugar level may become very high before a person seeks medical care. Symptoms of very high blood sugar include:

Flushed, hot, dry skin.

Loss of appetite, abdominal pain, and vomiting.

A strong, fruity breath odor (similar to nail polish remover or acetone).

Fast and shallow breathing.

Restlessness, drowsiness, difficulty waking up, confusion, or coma.



13



Symptoms of type 2 diabetes are essentially the same as those seen in type 1 but will develop more gradually

Other symptoms may include:

Slow-healing sores or cuts

Itching of the skin (usually in the vaginal or groin area)

Yeast infections

Recent weight gain



14



The management principals for diabetes mellitus are directed at control rather than cure. It is essential to maintain as near to normal blood glucose levels as possible by balancing food intake with medication and activity. Maintain blood cholesterol and triglyceride levels as near their normal ranges as possible by decreasing the total amount of fat to 30% or less of total daily calories and by reducing saturated fat and cholesterol. Control blood pressure at or below 130/80. These principals are designed to slow or possibly prevent the development of diabetes-related health problems such as retinopathy, nephropathy, vascular and neurologic changes and of course the pedal manifestations of diabetes.



15



Effective treatment can only be gained when the patient and the physician effectively communicate expectations and realistic goals.

The first principal is proper diet and weight control involving planning what’s eaten in a balanced meal plan. Next is regular exercise. It is of interest that exercise has been viewed as so important and issue in the fight against obesity that it is being added to the U.S. Government’s Food Pyramid. If required oral agents or insulin or both are prescribed, and patients must closely follow guidelines dosage and timing.. This requires close monitoring of blood glucose at home. All this must be maintained via frequent follow-up with laboratory testing and the health care provider.



16



The following chart is a summary of the goals of therapy for patients with diabetes based on the ADA 2003 Clinical Practice Recommendations Hemoglobin A1C should be keep less that 7% Preprandial plasma glucose levels should be between 90-130mg/dl Postprandial plasma glucose levels should be less that 180mg/dl Blood pressure should be less than 130/80 Low density lipoproteins should be less that 100mg/dl Tryglycerides should be less than 150 mg/dl and high density lipoproteins should be greater than 40mg/dl



17



The new recommendations from the 2004 Clinical Practice Recommendations are for a hemoglobin A1C less that 6 verses last years value of less than 7



18



The hypertension recommendations for blood pressures less than 130 systolic and over 80 diastolic haven’t changed however the 2004 recommendations recommend behavioral therapy alone for a period of 3 months and then adding medication if not effective. The strength of the evidence upon which this is bases is an E level recommendation and for blood pressures over 140 systolic and over 90 diastolic both behavioral and drug treatment. The strength of the evidence upon which this is bases is an A level recommendation



19



The new recommendations regarding lipids include lifestyle modification-decreased saturated fat and cholesterol, weight loss, exercise, smoking cessation and pharmacologic therapy: with statins, fibrates or combinations both based on A level evidence.



20



New recommendations regarding anti platelet therapy include Daily aspirin 75-162 mg/day for secondary prevention for MI, Vascular bypass, stroke, TIA, PVD, claudication and/or angina and Daily aspirin 75-162 mg/day for the primary prevention for MI, Vascular bypass, stroke, TIA, PVD, claudication and/or angina base on A level evidence



21



New recommendations regarding retinopathy include patients with diabetes should have a initial dilated eye examination shortly after diagnosis and Subsequent exams should be repeated annually unless an eye care professional advises less frequent exams (2-3 years) Both are based on B level evidence.



22



New recommendations regarding footcare include Annual foot exam

More frequent in high risk foot Patients with neuropathy should have a visual inspection every visit Neurologic exam in low-risk foot should include sensory exam with a 5.07 Semmes-Weinstein monofilament and Initial visit for PVD should include history of claudication, pedal pulses and an ABI It is interesting to note that these are all E level recommendation indicating the need for more research into the efficacy of these recommendations.



23



Lets turn our attention to an overview of the principal of treatment. The first principal of treating patients with diabetes is to control diet and maintain an appropriate level of physical activity. Ironically this is the least expensive and least followed management strategy as it requires significant effort on the part of the patient often requiring behavior modification



24



The overall goal of diabetes management is to attain and maintain optimal metabolic outcomes so that Normal blood glucose levels, appropriate lipid and lipoprotein levels, and Normal blood pressure levels can be maintained. I cannot overemphasis the need to prevent obesity. Ultimately we should all Make healthier food choices



25



There is strong evidence A – level recommendations for incorporating Whole grains, vegetables, and low fat milk into the diet. This is based on the findings that Total carbohydrates are more important than source or type, Sucrose does not need to be restricted but needs to be covered with extra glucose lowering medications And Non-nutritive sweeteners are safe consumed in acceptable levels.



26



There is some evidence at the B-level that adjusting pre-meal insulin based on carbohydrate content of meals may be effective and that Patients with diabetes need not take fiber in amounts greater than those recommended for non-diabetic persons however there is Insufficient evidence that low-glycemic diets provide any long term benefit



27



There is only limited evidence at the C level that insulin takers should try to be consistent in day to day carbohydrate intake



28



In the absence of significant controlled studies expert and consensus opinion at the E level suggest that Carbohydrate and monounsaturated fat should make up 60-70% of diet and that Sucrose and sucrose containing foods should be eaten in the context of a healthy diet.



29



There is fair evidence that B- Level that Protein ingestion does not increase plasma glucose concentration And that Protein requirement may be greater in poorly controlled patients



30



There is No evidence that protein intake should be modified if renal function is normal that said the Long term effects of high protein, low carbohydrate diets are unknown. This is based on E level evidence



31



Regarding fat intake there is strong evidence A level to suggest that saturated fat should not exceed 10% of energy intake and that daily cholesterol intake should be less than 300mg per day. There is fair evidence B level that patients should reduced saturated fat or replace with monounsaturated fat when weight loss is a goal or carbohydrates if weight loss is not a goal.



32



There is fair evidence B level that patients with diabetes should limit intake of transfats and that reduced fat diets may result in modest weight loss and improvement in dyslipedemia



There is poor evidence C- level that polyunsaturated fat intake should account for 10% of energy intake



33



Obesity is the number one public health issue in the united states and is associated with every chronic degenerative disease including diabetes. As such there is strong evidence that A- level

Reduced energy intake and modest weight loss improve insulin resistance in the short term.

Lifestyle changes of diet and exercise can produce long term weight loss

Exercise and behavior modification are the most useful strategies for maintaining weight loss

And Standard diets used alone are unlikely to result in long term weight loss.



34



There is fair evidence B-level that there is no clear evidence about the benefit of vitamin and mineral supplementation, and that routine long term antioxidant supplementation is not advised. There is fair evidence however that limiting alcohol to one drink per day for woman and two drinks per day for men should be recommend.



35



All of us need regular physical activity to maintain ideal weight and achieve a maximum functional potential, for patients with diabetes it needs to be a prescribe part of their daily activity.



36



The benefits of exercise are well established .Exercise Improves insulin metabolism, Helps to decrease and control weight, Improves muscle strength,Increases bone density and strength, Lowers blood pressure, helps to protect against heart and blood vessel disease by lowering overall cholesterol , it May raise HDL, or "good" cholesterol it enhances work capacity by increases energy level. Reduces stress, promotes relaxation, and releases tension and anxiety. Once again this is a low cost strategy that should be encourage and facilitated by providing a list of health clubs and community based programs that patients can participate in at low or no cost.



37



Before you prescribe an exercise program for your patients with diabetes they should Check with their primary care physician for cardiovascular risk, make any Adjustments to their medicine schedule or meal plan if necessary, make sure they Start slowly and gradually increase their endurance



To ensure exercise programs become a life long pursuit patients should Choose an activity that is enjoyable. Finally Exercise should be done at least three to four times per week for 20 to 40 minutes each session



38



The podiatrist is consulted by patients with diabetes to advise on exercise options based on their individual foot health status.



For patients where weight bearing exercise is not advisable, water exercise can be suggested due to the reduction of almost 80% of weight stress via buoyancy.



Standard recommendations by the ADA include 5 to 10-minute warm-up, 15 to 30 minutes of continuous aerobic exercise followed by a 5-minute cool down. To reduce the risk of hypoglycemia, the best time to exercise is 30 to 60 minutes after eating.



39



Further advise your patients that Prolonged or strenuous exercise can cause blood glucose to rise. Exercise is best completed when their medicine is reaching its peak effect. Patients should not ignore pain, pain is the only way the body has to tell us something’s wrong



Prevent dehydration by Drinking water before, during, and after exercise

Recommend Testing blood glucose before and after exercise



Patients should always carry a glucose source while exercising in case of hypoglycemia



40



If diet and exercise have not reduced obesity and controlled blood sugars, oral agents may become necessary.



41



Oral diabetes medicines help control blood glucose levels in people whose bodies still produce some insulin this includes the majority of people with type 2 diabetes). These drugs are NOT insulin, and are usually prescribed to people with diabetes along with recommendations for making specific dietary changes and getting regular exercise. Often, several of these drugs are used in combination to achieve optimal blood glucose control.



Remember that people with type 2 diabetes tend to have two problems that lead to increased glucose in the blood stream:



·Number 1They don't make enough insulin to move glucose into cells where it belongs.

And Number 2 The body's cells become "resistant" to insulin (know as insulin resistance), meaning they don't take in glucose as well as they should



42



What Types of Oral Diabetes Medicine Are Available?

Diabetes medications are grouped in categories based on medication type. There are several categories of oral diabetes medicine -- each works differently

Oral Agents

Sulfonylureas include: First generation medicine -- Dymelor, Diabinese, Orinase, Tolinase - and second generation medicine - Glucotrol, Glucotrol XL, DiaBeta, Micronase, Glynase PresTab, and Amaryl. These drugs lower blood glucose by stimulating the pancreas to release more insulin.



43



Biguanides, include Glucophage, Glucophage XR and metformin. These drugs improve insulin's ability to move glucose into cells especially in the liver.



44



Sulfonylureas and biguanide combination, including Glucovance. This drug stimulates the pancreas to release more insulin, improves insulin's action in the body, and lowers the amount of glucose released by the liver.



45



Thiazolidinediones, Actos and Avandia. These drugs improve insulin's effectiveness (improving insulin resistance) and lower the amount of glucose made by the liver.



46



Alpha-glucosidase inhibitors, including Precose and Glyset. These drugs block enzymes that help digest starches, slowing the rise in blood glucose. These drugs may cause diarrhea or gas.



47



Meglitinides, including Prandin and Starlix. These medicines lower blood glucose by stimulating the pancreas to release more insulin.



48



Finally the insulin replacement is always needed in Type 1 patients and may be needed in Type 2 patients in combination with an oral agent



49



BLANK



50



The following chart display’s the various types of insulin. It is not within the purview of this talk to delve in any great detail on this subject except to say that the three major groups include short acting, intermediate acting and long acting. Medical management of the systemic disease of diabetes is out of the scope of practice for podiatric physicians however close coordination of care with the primary care physician is essential to maintain good glycemic control. In addition in the surgical realm it is essential to modify the insulin dose to account for the effects of the trauma of surgery. This should be coordinated with the primary care physician.



51



In summary both the incidence and prevalence of diabetes is on the rise in the United States. As a result we are seeing a lot more of the morbid complications such as retinopathy, neuropathy, nephropathy, heart disease, and of course diabetic foot complications of neuropathy, ischemic and immunopathy.

It is essential that the podiatric physician be prepared to not only manage the pedal manifestation of the diabetes but must also play a role on the interdisciplinary management team by encouraging good glycemic control and appropriate diet and exercise.



52



The chronic hyperglycemia of diabetes is associated with long term damage, dysfunction and failure of various organs; especially the eyes, kidneys, nerves, heart and blood vessels. The risk of heart disease and stroke is 2-4 times greater in patients with diabetes. Diabetes is the leading cause of blindness, accounting for 12,000-24,000 new cases yearly. Sixty percent of non-traumatic amputations are seen in patients with diabetes mellitus. Forty three percent of kidney disease is related to diabetes mellitus. Prolonged periods of hyperglycemia may cause a decrease in chemotaxis, the ability to phagocytize, which results in decreased intracellular destruction of bacteria. Dr. Robbins reviews the Types of diabetes. Type 1 (pancreas produces little or no insulin), Type 2 (ineffective insulin production), Gestational diabetes and a new classification, ""prediabetes"". Management principles and goals of therapy are discussed with careful adherence to ADA guidelines. Dr. Robbins also cites changes in the new ADA guidelines. Oral medications for diabetes help control blood glucose levels in people whose bodies still produce insulin. Dr. Robbins discusses the oral medications that are available and their mechanisms of action. Type 1 diabetes patients always need insulin. The various types of insulin are reviewed, with particular attention to their speed of action and length of their activity.
Goals and Objectives
After participating in this activity, the viewer should be better able to:

1. Describe the pathogenesis of diabetes.
2. Recognize the significance of diabetes complications.
3. Discuss therapy recommendations.
4. Recognize the importance of nutrition and exercise in the treatment of diabetes.

Estimated time to complete this activity is 41 minutes.
Target Audience
Physicians, diabetes educators, and other health care professionals who treat patients with diabetes.
System Requirements
Diabetes Mellitus
Top
A Pentium-III class computer with a minimum of 256MB of system RAM is required to view Online Internet lectures. While a 56Kbps dial-up connection is supported, a Cable or DSL broadband Internet is strongly recommended for optimal video playback. You will need an up-to-date web browser such as Internet Explorer, Mozilla Firefox, or the AOL browser with Java and JavaScript enabled. Some lectures require the use of Internet Explorer to run and will not run with other browsers. Lectures may require the use of helper applications or plug-ins to access the materials. For example, most online lectures/presentations require either Adobe Flash Player or Windows Media Player (both free). To be able to print completion certificates Adobe Acrobat Reader must be installed.
Method of Participation
Diabetes Mellitus
Top
Complete the 4 steps to earn CE/CME credit:
  • Complete and submit the required pre-test
  • View Lecture
  • Complete and submit post-test and program evaluation. Credit will be issued with a passing score of 70% or better.
  • Click Print Certificate.
Disclosure Information
Diabetes Mellitus
Top
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.
Jeffrey M. Robbins, DPM has nothing to disclose
Privacy Policy
Diabetes Mellitus
Top
This web site will respect the confidentiality of the information that is transmitted on it in accordance with the provisions of this Agreement. The Web Site uses a random identifier, which is a session number attributed to the Registered User as he enters the site. This session number is expunged of the Web Site system as Registered User leaves. Please be advised that the Registered User's visit to the Web Site leaves a retrievable trace that allows the Web Site to gather raw data on the Registered User. Such technical retrieving system is necessary in order to secure the Web Site system.

This web site uses statistic and measurement systems which compile and process information such as IP numbers and number of visited pages. This information is processed in order to establish members' profiles and trends that may lead to, for example, market studies.

By registering to Web Site services, the Registered User agrees that his/her personal information may be archived in the members database of the Web Site and be used to transmit newsletters published by the Web Site and communications such as press releases or commercial information by the Host.

Information We Collect

In this section of our Privacy Policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors

Visitors to each of our Web sites can access the Web site's home page and browse some areas of the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you. On most of our Web sites, you must register with us to use the entire site.

Information We Collect When You Register

Customers registering for services on our Web sites are asked to provide us with identifying information, such as name, gender, contact information, and other personal information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion. You will also be given a choice about whether or not you want to receive newsletters and other information that we distribute from time to time. This PRESENT e-Learning Systems Web site will explain how personally identifiable information will be used and ask for your consent before collecting it.

Other Information

Discussion Boards: When you use a discussion board on one of our Web sites, you may post a message and your user name, which is available for all registered users to see. When you are posting publicly, any user of our Web site can see your message. You should not post any information you want or are required by law to keep private to a discussion board or other public forum on our Web sites.

My CV (Curriculum Vitae): On our web site, we offer an online data based profiling tool in which you supply information that is part of your curriculum vitae or professional resume. This tool stores the information that you provide on our servers. The information is accessible by other members and the public, and is designed to advertise you to the online community and allow other's to find you based on the information that you provide. We will always make it clear to you when information you provide to us through a tool will be saved.

Member Lookup: On our website, other members will be able to look you up and send you messages. If you opt not to be listed (blocked), no other members will be able to look you up.

In addition, we gather information about you that is automatically collected by our Web server, such as your IP address and domain name. We will use this information to personalize its offerings and presentations to you, facilitate your movements throughout our Web sites, provide personalized services, and to communicate with you individually.

Continuing Medical Education

When you register for a Continuing Medical Education ("CME") or a Continuing Education ("CE") activity through our web site, we collect certain personally identifiable information from you such as your name, email address and mailing address. We require that you provide the state in which you are licensed and your license number. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:

(i) We are accredited by the Accreditation Council for Continuing Medical Education ("ACCME") to provide continuing medical education for physicians, through a sponsorship agreement with the Mount Sinai School of Medicine. As an ACCME accredited entity, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years;

(ii) Commercial supporters of CME/CE activities on our Web site will receive only a data about CME/CE activities that are relevant to their interests and/or the courses they support;

(iii) Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities; and we may use the information we collect as otherwise permitted in this Privacy Policy.

Use of Cookies

Cookies are a technology we use to keep track of users as they move through our Web sites. Your browser allows us to place some information on your computer's hard drive that is associated with the computer you are using. We use cookies to personalize our Web sites and to track your usage across all of our Web sites. Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user, we may elect to associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web sites "remember" your user name and password and bypass the sign-in process on each visit to the site. Without cookies, this functionality would not be possible. Some of our business partners may use cookies on our site (for example, advertisers.) We have told them that we do not want them to use cookie information to track our users' activities once they leave our Web sites. However, because of the way advertisements are served on our Web sites, we do not have total control over how advertisers use cookies on our Web site. If you believe that one of our advertisers is placing an unwanted cookie on your hard drive, please contact privacy officer ( privacy@presentdiabetes.com ) to assist us in resolving the problem.

Uses We Make of Information

In this section of our Privacy Policy, we identify the ways we may use information about you that we have collected.

Aggregate Data

We collect data about visitors to our Web sites for product development and improvement activities. We also use it for market analysis. We may provide information from our Web sites in aggregate form, with identifying information removed, to third parties. For example, we may tell a health care partner what percentage of our registered users are of a particular medical specialty or have certain credentials. Any third party that receives our data must agree not to attempt to re-identify the people it belongs to. For example, we may provide information to a potential advertiser of a product that would appeal to a diabetes patient about what percentage of our users have diabetes. Depending on our agreement with the third parties, we may or may not charge for this information.

Marketing and Advertising

We may target our advertising or marketing depending on information we have about you. For example, a user that is a healthcare professional who treats diabetes may receive advertising for new diabetes therapies (although in neither case will the advertiser have access to any individually identifiable information about you). We may also personalize our Web site based on your interests. For example, you may see different articles in different places on our Web site based on information you have shared with us, or information we have gained by observing your previous behavior, or information we may have gained from your interactions with a third party that shares information with us. We use information for our own internal marketing, research, and related purposes. Third Parties In addition to aggregate information (discussed previously), we may share some kinds of personally identifiable information with third parties as described below.

Other Companies: We have strategic relationships with other companies who offer products and services on our Web sites. When you are interacting with those companies, different rules and privacy policies may apply. We do not control the collection or use of information you provide to these companies, but we do require that those companies clearly state their policies so you can decide whether to give them any information.

Our Employees and Consultants: We contract with other companies and individuals to help us provide services. For example, we may host some of our Web sites on another company's computers, hire technical consultants to maintain our Web-based tools, or work with companies to remove repetitive information from customer lists, analyze data, provide marketing assistance, and provide customer service. In addition, if you are a healthcare professional, we may validate your licensure status and other information against available databases that list licensed health care professionals. In order to perform their jobs, these other companies may have limited access to some of the personal information we maintain about our users. We require all such companies to comply with the terms of our Privacy Policy, to limit their access to any personal information to the minimum necessary to perform their obligations, and not to use the information they may access for purposes other than fulfilling their responsibilities to us. We use our best efforts to limit the use of other companies in areas where personally identifiable information may be involved.

Promotional Offers: Sometimes we send offers to selected groups of customers on behalf of other businesses. When we do this, we do not give that business your name and address. We provide a variety of mechanisms for you to tell us you do not want to receive such promotional offers. For example, we may provide an opt-in box for consumers to receive an email from another business, and we make clear that by opting in you are submitting your data to a third party.

Protection of Information

In this section of our Privacy Policy, we discuss the security measures we take to protect information that we have collected about you.

We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. We use security methods to determine the identity of its registered users, so that appropriate rights and restrictions can be enforced for that user. Reliable verification of user identity is called authentication. We use both passwords and usernames, as well as double opt-n verification, to authenticate users. Users are responsible for maintaining their own passwords.

Access to Information and Choices

In this section of our Privacy Policy, we tell you how to obtain and correct information we have about you, and how to choose what types of information you may share with us.

Correction of Information We Have About You

If you believe that registration information collected by our Web site(s) is in error, you may edit your personal profile any time that you like. You can directly edit most of your user profile on the Web site on which you initially registered. Information that you can not edit may only be changed by contacting Web Customer Support (see CONTACTS). Requests for deletion of your record may result in your removal from the registry, but we may keep certain demographic information about you for product improvement purposes. You may contact Web Customer Support and ask for the changes that you would like to make.

Our Employees

Our employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized employees are permitted to access personal information. Our employees with access to personally identifiable information are required to attend a confidentiality/privacy training class, and to sign a confidentiality agreement. All employees and contractors must abide by our Privacy Policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.
Copyright Statement
Diabetes Mellitus
Top
This website and its content is copyright of PRESENT eLearning Systems, LLC - © 2007-2012 All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited other than the following:

  1. You may print or download to a local hard disk extracts for your personal and non-commercial use only, and
  2. You may copy the content to individual third parties for their personal use, but only if you acknowledge the website as the source of the material

You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other website or other form of electronic retrieval system.